New Science Ventures

Pakal Technologies develops IGTO-based semiconductors designed to enhance the IGBT market. Their products utilize IGTO, a silicon device that serves as a direct replacement for IGBTs, offering improved performance and compatibility.

Glydways is a South San Francisco-based company specializing in affordable autonomous transportation systems. It designs, manufactures, installs, and operates efficient, high-capacity mobility solutions that are environmentally friendly with zero greenhouse gas emissions.

Glydways is a South San Francisco-based company specializing in affordable autonomous transportation systems. It designs, manufactures, installs, and operates efficient, high-capacity mobility solutions that are environmentally friendly with zero greenhouse gas emissions.

VUV Analytics, Inc. is a manufacturer and marketer of vacuum ultraviolet (VUV) detectors, specializing in advanced chemical analysis technologies. Founded in 2009 and based in Cedar Park, Texas, the company emerged as a spin-off from a semiconductor equipment firm, leveraging the expertise of its founders in hardware, software, and intellectual property related to VUV technologies. VUV Analytics produces instruments such as the VGA-100, a VUV absorption spectroscopy device, and gas chromatography detectors that facilitate the identification and quantification of various compounds. The company serves a diverse range of industries, including petroleum and natural gas, environmental science, specialty gases, petrochemicals, agrochemicals, forensics, and food and beverage safety. By harnessing light to create spectral signatures in the gas phase, VUV Analytics enhances the accuracy of chemical analysis, enabling customers to achieve unambiguous compound identification and quantitative results across complex applications.

Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.

Paragraf is a UK-based company specializing in graphene technology. Established in 2015, it focuses on developing high-purity graphene products for commercial applications, particularly in electronics. The company produces graphene electronic devices and sensors using contamination-free technology.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

Analog Inference is a company focused on advancing neural computing through innovative technology. Founded by experienced professionals from the computing industry and supported by Khosla Ventures, the company is developing its first generation of products. It specializes in deep sub-threshold analog in-memory computation, which allows for the execution of complex neural networks at full resolution while maintaining low latency and eliminating the need for active cooling. This technology enables the performance of data-center-grade artificial intelligence workloads with significantly reduced power consumption, facilitating the deployment of server-class networks in more cost-effective devices.

Founded in 2015, Phase Four specializes in developing electric propulsion systems for small satellites. Its signature product is the Radio Frequency Thruster (RFT), which offers significant cost savings, reduced size, and propellant flexibility while maintaining high performance. The company's solutions enable clients to maneuver satellites into various orbits economically.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Founded in 2014, Zeotap operates a customer intelligence platform that helps brands understand their customers and predict behaviors. Its platform connects various data assets across the global advertising ecosystem for end-to-end monetization, collects real-time data to maximize campaign impact, and generates strategic insights. Zeotap serves data owners and advertisers worldwide, with offices in Berlin, New York, Bengaluru, Madrid, and Milan.

ABL Space Systems is a company that designs and manufactures rockets specifically for launching small satellites. Founded in 2017 and headquartered in El Segundo, California, ABL focuses on developing low-cost and reliable launch vehicles. Its primary product, the RS1 rocket, is capable of carrying payloads of up to 1,350 kilograms to Low Earth Orbit (LEO) and supports various configurations, including multi-manifest and dedicated deployments. Additionally, ABL has developed the GS0 ground system to facilitate rapid deployment and integration of launch operations at multiple locations. The company operates out of a 30,000 square foot facility dedicated to research, development, and production.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

DUST Identity, Inc. specializes in developing advanced authentication technology that employs nano-diamonds to create an unclonable identity layer on various objects within supply chains. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, the company offers a proprietary system known as DUST, which includes an optical scanner and a cloud-based infrastructure. This system provides an interface for managing object identity and provenance, ensuring that products can be verified and trusted throughout their lifecycle. By linking physical items to their digital records, DUST Identity enables businesses to access critical data regarding product sourcing, testing, and certification, thereby enhancing safety and traceability across their value chains.

PlanetiQ LLC, founded in 2012 and based in Bethesda, Maryland, specializes in launching satellites designed to enhance weather forecasting, climate monitoring, and space weather prediction. The company leverages commercial satellite constellations to deliver critical weather data, addressing the increasing demand for precise forecasts amidst rising natural disaster costs and expanding populations. Traditional government-funded satellite programs have struggled to adapt to modern technological needs, resulting in aging spacecraft and budget constraints that jeopardize essential data collection. PlanetiQ aims to fill these gaps by providing timely and accurate data, which is vital for monitoring day-to-day weather events such as hurricanes, floods, and droughts, as well as long-term climate trends. Their services are intended to improve safety, reduce weather-related risks, and support decision-making across various sectors.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

DUST Identity, Inc. specializes in developing advanced authentication technology that employs nano-diamonds to create an unclonable identity layer on various objects within supply chains. Founded in 2011 and headquartered in Framingham, Massachusetts, with an additional office in Princeton, New Jersey, the company offers a proprietary system known as DUST, which includes an optical scanner and a cloud-based infrastructure. This system provides an interface for managing object identity and provenance, ensuring that products can be verified and trusted throughout their lifecycle. By linking physical items to their digital records, DUST Identity enables businesses to access critical data regarding product sourcing, testing, and certification, thereby enhancing safety and traceability across their value chains.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

Isorg SA, founded in 2010 and based in Grenoble, France, specializes in the development and manufacturing of organic and printed electronic devices, particularly in the fields of photonics and image sensors. The company is noted for its innovative high-performance opto-electronic sensors, which can be integrated into various products, transforming surfaces made of plastic or glass into smart interfaces. Isorg offers a comprehensive range of services, from proof-of-concept to mass production, catering to diverse applications across consumer electronics, home appliances, smart buildings, industrial sectors, healthcare, and safety. Additionally, the company provides support for product development and integration. Its technology includes large-area image sensors and photodetectors, contributing to sectors such as medical imaging, non-destructive testing, and data security.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.

ChromaCure is a biotechnology company focused on developing innovative cancer therapies. The company specializes in discovering first-in-class small molecule therapeutics that address unmet needs in oncology. ChromaCure's primary goal is to identify potential new drug candidates that selectively and potently inhibit cancer targets, offering novel treatment options for various forms of cancer. These therapies are designed to be used either as monotherapy or in combination with existing treatments such as immunotherapy or chemotherapy, aiming to provide more effective solutions for cancer patients.

Escalier Biosciences B.V. is a biopharmaceutical company based in Nijmegen, the Netherlands, specializing in the development of small molecule therapeutics aimed at treating autoimmune disorders, particularly psoriasis. Founded in 2016, the company is engaged in creating innovative drug candidates that effectively target ROR?t, a critical regulator in the inflammatory process. Escalier's lead products, which are designed for both topical and oral administration, are currently in late-stage preclinical studies. These therapeutics are formulated to enhance penetration in dermal tissues, thereby maximizing target engagement at sites of inflammation while minimizing systemic drug activity and associated side effects. In addition to its operations in the Netherlands, Escalier has an office in Encinitas, California.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Founded in 2014, Zeotap operates a customer intelligence platform that helps brands understand their customers and predict behaviors. Its platform connects various data assets across the global advertising ecosystem for end-to-end monetization, collects real-time data to maximize campaign impact, and generates strategic insights. Zeotap serves data owners and advertisers worldwide, with offices in Berlin, New York, Bengaluru, Madrid, and Milan.

Caringo, Inc. is a software company specializing in object storage solutions designed for managing unstructured data. Founded in 2005 and based in Austin, Texas, the company offers a range of products including its flagship CAStor, which facilitates private cloud storage and enables customers to build storage clusters without reliance on proprietary hardware. Other notable offerings include the Content Router for automated data distribution, the FileFly platform for managing infrequently accessed data on Microsoft Windows servers, and the Elastic Content Protection solution for adaptable data protection based on varying storage requirements. Additionally, Caringo provides tools such as CloudScaler for cloud storage as a service, Indexer for data insights, and Swarm, which addresses challenges in big data storage and content delivery. Its clientele ranges from small to medium-sized businesses to Fortune 500 companies, reflecting its broad applicability in the data management landscape.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

VUV Analytics, Inc. is a manufacturer and marketer of vacuum ultraviolet (VUV) detectors, specializing in advanced chemical analysis technologies. Founded in 2009 and based in Cedar Park, Texas, the company emerged as a spin-off from a semiconductor equipment firm, leveraging the expertise of its founders in hardware, software, and intellectual property related to VUV technologies. VUV Analytics produces instruments such as the VGA-100, a VUV absorption spectroscopy device, and gas chromatography detectors that facilitate the identification and quantification of various compounds. The company serves a diverse range of industries, including petroleum and natural gas, environmental science, specialty gases, petrochemicals, agrochemicals, forensics, and food and beverage safety. By harnessing light to create spectral signatures in the gas phase, VUV Analytics enhances the accuracy of chemical analysis, enabling customers to achieve unambiguous compound identification and quantitative results across complex applications.

Kateeva specializes in manufacturing inkjet printing equipment for producing organic light-emitting diode (OLED) displays. Its technology enables high-volume, large-area production of OLEDs with improved lifetimes and lower costs.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

Akarna Therapeutics Ltd. is a biopharmaceutical company focused on developing small molecule therapeutics for inflammatory and fibrotic diseases. Established in 2014, the company operates out of offices in Cambridge, United Kingdom, and San Diego, California. Akarna's lead program centers on a non-bile acid FXR agonist, which aims to provide a best-in-class therapeutic option for treating nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease with no currently approved treatments. At present, the lead candidate is undergoing preclinical studies, including IND-enabling toxicology and safety pharmacology assessments, with plans to initiate first-in-human trials.

Ovizio develops digital holographic interferometric microscopy products. It specializes in creating four-dimensional microscopic imaging devices and software based on digital holographic microscopy for life sciences research and bioprocessing.

Fuzzy Logix, LLC is an analytics software and professional services company based in Charlotte, North Carolina, founded in 1995. The company specializes in in-database analytics solutions, which allow organizations to perform complex analytical computations directly within their databases, eliminating the need for data extraction and intermediate processing. Its primary product, DB Lytix, serves quantitative analysts and application developers by accelerating model development and enabling in-database scoring. Fuzzy Logix also offers a range of financial analytics solutions, a graphics processing unit analytic appliance loaded with a comprehensive library of algorithms, and text and name matching capabilities. In addition to its software offerings, Fuzzy Logix provides various advisory services, including analytics and technology consulting, cloud analytics, managed services, and custom model development. The company caters to diverse sectors, including finance, insurance, marketing, retail, and healthcare, and distributes its products both directly and through resellers, serving clients in the United States and internationally.

EXTEN Technologies, Inc. specializes in designing, developing, and manufacturing high-performance non-volatile memory flash storage solutions tailored for web-scale, enterprise, and cloud data centers. Founded in 2011 and based in Austin, Texas, the company focuses on accelerating application workloads while minimizing system power consumption. EXTEN Technologies provides a range of products, including flash storage arrays and solid-state drives, alongside support and service planning, training, and professional design services. Its storage solutions are engineered to meet the demands of high-performance, low-latency workloads prevalent in sectors such as e-commerce, real-time analytics, video processing, and financial trading. Serving a global clientele through an extensive network of resellers and partners, EXTEN Technologies is recognized as a pioneer in ultra-high-performance storage software applications. As of August 2020, it operates as a subsidiary of OVH SAS.

VORAGO Technologies is a fabless semiconductor company that develops radiation‑hardened and extreme temperature‑hardened integrated circuits for high‑reliability markets. The firm designs high‑density SRAMs, microcontrollers, and logic ICs using its patented HARDSIL technology, which hardens commercial CMOS processes without redesign. It also offers custom ASIC design services through a hardened Metal Programmable System‑on‑Chip platform. Founded in 2004 and headquartered in Austin, Texas, VORAGO provides components for automotive, industrial, military, aerospace, and networking applications that require robust performance in harsh environments.

Ralexar Therapeutics develops topical and systemic therapies based on Liver X Receptor modulators to treat dermatological inflammatory disorders, including atopic dermatitis. Founded in 2013 and based in Pennsylvania, the company initially advanced ALX-101, a topical LXR-based therapy, and later changed its name from Alexar Therapeutics to Ralexar Therapeutics in 2016. The programs focus on modulating Liver X Receptor pathways to address cutaneous inflammation through novel formulations, aiming to initiate treatment earlier to improve outcomes in inflammatory skin diseases.

PerceptiMed, Inc. is a technology company based in Mountain View, California, specializing in medication verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. Founded in 2011, the company offers a range of products, including the IdentRx automated medication-verification device, which ensures accurate prescription pill verification and administration. Complementing this device is IdentRx Remote, software that facilitates remote verification of dispensed pills, and MedPass, a system aimed at preventing errors in pill administration. Additionally, PerceptiMed provides ScripClip, an electronic tagging system to enhance medication management. The company's innovative VeriFill technology ensures 100% verification of drug, dosage, and manufacturer for each pill dispensed, positioning PerceptiMed as a leader in the healthcare technology sector.

Vaultive is a provider of cloud data encryption services that addresses critical concerns surrounding cloud data security. The company offers a unique encryption in use technology that allows organizations to retain control and ownership of their data, even when it resides in the cloud. By enabling customers to hold the encryption keys, Vaultive empowers businesses to utilize cloud applications effectively while ensuring compliance, governance, and security. Its services facilitate the processing of encrypted data within cloud applications, allowing for tasks such as searching, indexing, and sorting without the need for decryption. This approach enables organizations to benefit from the efficiency and cost-effectiveness of cloud computing while maintaining the data security and control typically associated with on-premise solutions.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, specializing in epigenetic tools that aim to transform medical diagnostics. Founded in 2012 as a spin-out from the University of Cambridge, the company is pioneering the clinical applications of epigenetics, particularly through its innovative TrueMethyl technology. This includes oxidative bisulfite sequencing, which allows for the precise sequencing of hydroxymethyl cytosine and methylcytosine at single-base resolution. Cambridge Epigenetix offers a range of products, such as TrueMethyl 6 and TrueMethyl 24 kits, designed for the quantitative measurement and analysis of these critical epigenetic markers. The company’s research highlights the significance of 5-hydroxymethylcytosine as a biomarker for various diseases, including colorectal cancer, and aims to simplify diagnostic processes to a simple blood draw. The firm collaborates with third-party vendors and sells its products directly to business customers both in the UK and internationally.

Kateeva specializes in manufacturing inkjet printing equipment for producing organic light-emitting diode (OLED) displays. Its technology enables high-volume, large-area production of OLEDs with improved lifetimes and lower costs.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.

Ario Pharma Ltd is engaged in the development of therapeutic drugs aimed at treating respiratory conditions. The company is focused on evaluating the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, through Phase 2 clinical trials. In addition to its respiratory focus, Ario Pharma is also developing a range of small-molecule TRPV1 antagonists that target neuropathic and inflammatory pain. The company is backed by a highly experienced development team and is supported by leading experts in respiratory disease, ensuring a robust approach to drug development.

BrightVolt, Inc. is a company focused on the design, development, and large-scale manufacturing of ultra-thin film batteries tailored to power a range of Internet-connected devices, including medical patches, sensor labels, and power cards. It specializes in creating custom solid-state thin film batteries and power solutions for clients' Internet of Things (IoT) devices, along with its proprietary Flexion solid-state thin film lithium polymer batteries and microelectronic components. BrightVolt's innovative technologies enhance battery chemistry, offering increased stability and safety in lithium-polymer batteries. The company's products are distributed both in the United States and internationally. Founded in 1998 and headquartered in Redmond, Washington, BrightVolt was previously known as Solicore, Inc.

Dezima Pharma B.V., founded in 2012 and located in Naarden, the Netherlands, specializes in the development of protein-based compounds aimed at treating cardiovascular diseases associated with dyslipidemia. The company focuses on creating innovative drug therapies, particularly a cholesteryl ester transfer protein inhibitor, which is designed to reduce low-density lipoprotein cholesterol levels. This pharmacological approach aims to lower the risk of cardiovascular diseases, thereby providing clinicians with effective treatment options for dyslipidemic patients.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product candidates, RSLV-132 and RSLV-133, which are designed to target and degrade immune complexes that contribute to disease pathology. RSLV-132 is a mono-specific nuclease Fc-fusion protein aimed at preventing interferon activation and mitigating kidney damage, while RSLV-133 combines two different nuclease activities into a single therapeutic molecule. Founded in 2010, Resolve Therapeutics is rooted in pioneering research from the University of Washington School of Medicine, with a commitment to improving the lives of patients suffering from these chronic conditions.

Achronix Semiconductor Corp. is a privately held fabless semiconductor company based in Santa Clara, California, specializing in the development of high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, utilizes Intel's advanced 22nm process technology and integrates hard IP protocol functions tailored for communications applications. Achronix also provides Speedcore eFPGA IP for integration into customers' system-on-chips (SoCs) aimed at compute and network acceleration. The company offers a robust design-tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. Achronix serves a variety of markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Founded in 2004, Achronix distributes its products through a network that spans North America, Europe, Israel, China, and Russia, with additional research and development facilities located in Bangalore, India.

Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing regenerative therapies. Founded in 2007, it focuses on treating life-threatening diseases using non-viral gene therapies that activate natural processes to repair the body.

Vaultive is a provider of cloud data encryption services that addresses critical concerns surrounding cloud data security. The company offers a unique encryption in use technology that allows organizations to retain control and ownership of their data, even when it resides in the cloud. By enabling customers to hold the encryption keys, Vaultive empowers businesses to utilize cloud applications effectively while ensuring compliance, governance, and security. Its services facilitate the processing of encrypted data within cloud applications, allowing for tasks such as searching, indexing, and sorting without the need for decryption. This approach enables organizations to benefit from the efficiency and cost-effectiveness of cloud computing while maintaining the data security and control typically associated with on-premise solutions.

TigerConnect is a leading provider of secure, real-time communication solutions in healthcare. Its platform facilitates teamwork among doctors, nurses, patients, and care providers through text, video, and voice communication. Trusted by over 4,000 organizations, TigerConnect maintains high uptime and processes millions of messages daily. Headquartered in Santa Monica, California, the company was founded in 2010.

Founded in 2006, Oxyrane UK Limited is a biopharmaceutical company based in Manchester, United Kingdom. It develops novel enzyme replacement therapies using its proprietary glycoengineering platform to treat lysosomal storage diseases.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product candidates, RSLV-132 and RSLV-133, which are designed to target and degrade immune complexes that contribute to disease pathology. RSLV-132 is a mono-specific nuclease Fc-fusion protein aimed at preventing interferon activation and mitigating kidney damage, while RSLV-133 combines two different nuclease activities into a single therapeutic molecule. Founded in 2010, Resolve Therapeutics is rooted in pioneering research from the University of Washington School of Medicine, with a commitment to improving the lives of patients suffering from these chronic conditions.

Lightwire is a telecommunications company focused on developing innovative interconnect solutions that enhance networking, communication, server, and storage systems. The company specializes in the integration of optical and electrical technologies, primarily utilizing CMOS photonics to create high-speed interconnects. Its product offerings include Ethernet optoelectronic interconnects and optical transceiver modules, designed to facilitate seamless, plug-and-play 10Gbps interfaces between computers, servers, and Ethernet-based network equipment. Lightwire's mission is to support the next generation of telecommunications infrastructure through efficient and effective connectivity solutions for businesses.

Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.

ProterixBio, Inc. is a biomedical company based in Billerica, Massachusetts, focused on developing disease management platforms for chronic respiratory diseases. The company specializes in proprietary blood-based biomarker tests aimed at transforming the management of conditions such as chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. ProterixBio's ViBE platform, along with its Acoustic Membrane MicroParticle (AMMP) assays, facilitates the precise analysis of proteins in various sample types, delivering real-time biological assessments of a patient's disease state. This technological innovation enhances the sensitivity and specificity of traditional testing methods, allowing healthcare providers to make informed decisions that help reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. Founded in 2002, ProterixBio seeks to address the unmet needs in chronic care management through its advanced diagnostic capabilities.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Achronix Semiconductor Corp. is a privately held fabless semiconductor company based in Santa Clara, California, specializing in the development of high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, utilizes Intel's advanced 22nm process technology and integrates hard IP protocol functions tailored for communications applications. Achronix also provides Speedcore eFPGA IP for integration into customers' system-on-chips (SoCs) aimed at compute and network acceleration. The company offers a robust design-tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. Achronix serves a variety of markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Founded in 2004, Achronix distributes its products through a network that spans North America, Europe, Israel, China, and Russia, with additional research and development facilities located in Bangalore, India.

Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.

TherOx, Inc., established in 1994 and headquartered in Irvine, California, is a privately-held medical device company focused on improving heart attack treatment standards. It specializes in developing dissolved oxygen delivery systems, notably its SuperSaturated Oxygen Therapy (SSO2), which involves creating supersaturated oxygenated blood using the TherOx DownStream system for delivery to coronary arteries. This therapy has shown promise beyond initial heart attack treatment, with potential applications in stroke, oncology, and wound care. As of June 18, 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation. The company holds 20 issued patents, with more pending, reflecting its extensive research and development efforts.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Ikonisys, Inc. is a medical diagnostic company focused on the design, manufacture, and marketing of advanced diagnostic products for cancer detection and genetic disorder screening. Headquartered in New Haven, Connecticut, Ikonisys offers a range of innovative tools, including the Ikoniscope Robotic Microscope, which automates slide handling and image analysis, reducing human error in testing. Their product line features various oncoFISH applications, such as those for bladder cancer and HER2 status in breast tissue, as well as tools for detecting genetic abnormalities in prostate tissue biopsies. The company is committed to transforming diagnostic medicine by enabling early and accurate disease detection through a combination of cutting-edge technology and scientific research, ultimately assisting healthcare professionals in providing optimal patient care. Founded in 1999, Ikonisys continues to advance its capabilities in non-invasive diagnostic solutions.

FlowCardia, Inc. is a medical device company established in 2002 that specializes in developing innovative catheter-based technologies aimed at facilitating guidewire crossing of chronic total occlusions (CTOs) in both coronary and peripheral arteries. CTOs pose significant challenges in interventional therapy, often leading to patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia is dedicated to addressing this critical need within the medical community by providing advanced solutions that enhance the safety and efficacy of CTO recanalization.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Xoft, Inc. specializes in the development of electronic brachytherapy (eBx) systems designed for radiation oncology applications. The company’s flagship product, the Axxent Controller, employs a miniaturized high dose rate X-ray source to deliver targeted radiation directly to cancerous tumor beds. Xoft also provides a range of applicators, including the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, the company offers a variety of accessories to support its products, such as physics accessory kits and protective shields to minimize radiation exposure to healthy tissues. Xoft’s innovative solutions are primarily utilized in the treatment of early-stage breast cancer, skin cancer, and endometrial cancer, and the products are distributed through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, Xoft was previously known as Xoft microTube, Inc. before rebranding in 2004.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapeutics aimed at addressing significant unmet medical needs. Founded by seasoned pharmaceutical executives, the company is engaged in the commercialization of novel drugs and therapies for challenging illnesses. Ception's portfolio includes Reslizumab, which targets eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents designed for potential oral administration. In addition, the company is actively developing treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. Ception's research efforts are focused on creating new compounds and exploring new indications for existing therapies, underscoring its commitment to advancing healthcare solutions.

Achronix Semiconductor Corp. is a privately held fabless semiconductor company based in Santa Clara, California, specializing in the development of high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Its flagship product line, Speedster22i, utilizes Intel's advanced 22nm process technology and integrates hard IP protocol functions tailored for communications applications. Achronix also provides Speedcore eFPGA IP for integration into customers' system-on-chips (SoCs) aimed at compute and network acceleration. The company offers a robust design-tool suite known as the Achronix CAD Environment (ACE), which supports industry-standard synthesis tools. Achronix serves a variety of markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Founded in 2004, Achronix distributes its products through a network that spans North America, Europe, Israel, China, and Russia, with additional research and development facilities located in Bangalore, India.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Ikonisys, Inc. is a medical diagnostic company focused on the design, manufacture, and marketing of advanced diagnostic products for cancer detection and genetic disorder screening. Headquartered in New Haven, Connecticut, Ikonisys offers a range of innovative tools, including the Ikoniscope Robotic Microscope, which automates slide handling and image analysis, reducing human error in testing. Their product line features various oncoFISH applications, such as those for bladder cancer and HER2 status in breast tissue, as well as tools for detecting genetic abnormalities in prostate tissue biopsies. The company is committed to transforming diagnostic medicine by enabling early and accurate disease detection through a combination of cutting-edge technology and scientific research, ultimately assisting healthcare professionals in providing optimal patient care. Founded in 1999, Ikonisys continues to advance its capabilities in non-invasive diagnostic solutions.

Light Sciences Oncology, Inc. is a biotechnology company focused on developing and manufacturing talaporfin sodium, a water-soluble drug for the treatment of solid tumors and other medical indications. The company specializes in providing innovative oncology solutions, including a single-use, LED-based drug activator that delivers a precise light dose to enhance treatment efficacy. Its primary applications include the treatment of hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994 and headquartered in Bellevue, Washington, Light Sciences Oncology combines advanced drug development with a commitment to improving patient care through non-invasive treatment options.

TherOx, Inc., established in 1994 and headquartered in Irvine, California, is a privately-held medical device company focused on improving heart attack treatment standards. It specializes in developing dissolved oxygen delivery systems, notably its SuperSaturated Oxygen Therapy (SSO2), which involves creating supersaturated oxygenated blood using the TherOx DownStream system for delivery to coronary arteries. This therapy has shown promise beyond initial heart attack treatment, with potential applications in stroke, oncology, and wound care. As of June 18, 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation. The company holds 20 issued patents, with more pending, reflecting its extensive research and development efforts.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.